Moreover, the efficacy and safety of lenabasum, a novel oral CB2 agonist, is currently under investigation in multiple autoimmune and fibrotic diseases, including SLE and systemic sclerosis [54]. This evidence concerns the gene CNR2 and systemic lupus erythematosus.